Research Analysts’ Weekly Ratings Changes for Trevena (TRVN)

Trevena (NASDAQ: TRVN) recently received a number of ratings updates from brokerages and research firms:

• 4/14/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/6/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 4/2/2024 – Trevena had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 3/29/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/21/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/13/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 3/5/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/26/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 2/18/2024 – Trevena is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Trevena Trading Up 1.3 %

Shares of TRVN stock opened at $0.40 on Thursday. Trevena, Inc. has a 12-month low of $0.30 and a 12-month high of $3.28. The company has a market capitalization of $7.30 million, a P/E ratio of -0.13 and a beta of 1.10. The firm has a 50-day moving average price of $0.51 and a 200 day moving average price of $0.58. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 8.35.

Hedge Funds Weigh In On Trevena

A number of institutional investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new position in shares of Trevena in the fourth quarter worth about $576,000. Jump Financial LLC bought a new position in shares of Trevena in the third quarter worth about $27,000. Renaissance Technologies LLC raised its stake in shares of Trevena by 158.3% in the second quarter. Renaissance Technologies LLC now owns 182,152 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 111,620 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Trevena by 166.2% in the first quarter. Jane Street Group LLC now owns 45,330 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 28,303 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Trevena in the fourth quarter worth about $40,000. 13.56% of the stock is owned by institutional investors.

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.